Latest news

• EU grants conditional approval to Roche's lymphoma drug Polivy

  The EU approval clears Polivy for use in combination with chemotherapy drug bendamustine and anti-CD20 rituximab in adults with relapsed/refractory  diffuse large B-cell lymphoma (DLBCL) who are ineligible ... Filings for approval in first-line DLBCL

• Incyte signs lymphoma deal worth up to $1.1bn with MorphoSys

  This includes trials of tafasitamab in non-Hodgkins lymphoma, chronic lymphocytic leukaemia (CLL), relapsed/refractory diffuse large B cell lymphoma (r/r DLBCL) and frontline DLBCL. ... beyond DLBCL, such as follicular lymphoma (FL), marginal zone

• AstraZeneca’s Calquence impresses in previously untreated CLL

  However, there is also new competition in the lymphoma market from newcomer BeiGene – the Chinese-drugmaker recently won approval in the US for its MCL therapy  Brukinsa (zanubrutinib). ... It is also in clinical development for a host of other blood

• AstraZeneca wins FDA approval for Calquence in chronic lymphoma

  and small lymphocytic lymphoma (SLL), taking the fight to AbbVie/Johnson &Johnson’s Imbruvica. . ... The Chinese drugmaker's therapy is also in clinical development for CLL, SLL, follicular lymphoma and marginal zone lymphoma.

• BeiGene bags FDA approval for first product Brukinsa in lymphoma

  China’s BeiGene has claimed its first-ever product approval in the US, getting an FDA nod for its mantle cell lymphoma (MCL) therapy Brukinsa. ... It’s also under regulatory review in China and Europe for MCL, as well as being in clinical development